Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

The Agency for Healthcare Research and Quality’s (AHRQ) Technology Assessment Program will be posting a draft technology assessment for review on January 27, 2010. This draft is entitled “Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.” If you are interested in reviewing this document, please visit: https://www.ahrq.gov/clinic/ta/tareview.htm. The document will be available for review from 9:00 AM on January 27, 2010 to 5:00 PM on February 10, 2010. If you have any questions, please contact ahrqtap@ahrq.hhs.gov.